Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
11°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Abeona Therapeutics
(NQ:
ABEO
)
6.002
+0.022 (+0.37%)
Streaming Delayed Price
Updated: 9:56 AM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Abeona Therapeutics
< Previous
1
2
3
4
5
6
Next >
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
September 07, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission
August 30, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
August 02, 2023
Via
Benzinga
Recap: Abeona Therapeutics Q1 Earnings
May 11, 2023
Via
Benzinga
Cantor Bullish On Abeona Saying Recent Trial Data 'Best Case Scenario'
November 08, 2022
Via
Benzinga
Abeona Therapeutics Touts Positive Data From Pivotal EB-101 Study In Blistering Skin Disorder
November 03, 2022
Via
Benzinga
Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023
July 28, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Joins Rare Disease Company Coalition
July 19, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
July 07, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
July 03, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101
June 09, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023
May 22, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 16, 2023
Animal proof-of-concept for AAV-based gene therapies for Stargardt disease, X-linked retinoschisis and autosomal dominant optic atrophy
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Reports First Quarter 2023 Financial Results
May 11, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Additional Phase 3 VIITAL™ Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting
May 11, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
April 10, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
March 29, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants
March 24, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting
March 16, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Update on AAV Ophthalmology Program
March 14, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Three Small-Cap Biotech Stocks to Consider Now
December 12, 2022
This article looks at three small-cap biotech companies with stock prices that are making significant moves and have a bright outlook for 2023
Via
MarketBeat
PXMD, GETY: The Top 5 Short Squeeze Stocks to Watch This Week
November 21, 2022
We're checking in on the top short squeeze stocks to watch this week as traders continue to have an interest in this part of the market!
Via
InvestorPlace
PaxMedica, Getty Images And 3 Short Squeeze Candidates That Could Soar This Week
November 21, 2022
Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move.
Via
Benzinga
Abeona Therapeutics Reports Third Quarter 2022 Financial Results
November 14, 2022
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces $35 Million Private Placement Financing
November 03, 2022
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101
November 03, 2022
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
October 19, 2022
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Why Laser Photonics Shares Surged By Around 19%; Here Are 70 Biggest Movers From Friday
October 17, 2022
Gainers Agrify Corporation (NASDAQ: AGFY) climbed 53.8% to close at $1.45. FedNat Holding Company (NASDAQ: FNHC) gained 48% to settle at $0.52.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.